Fig. 1.
Partitioned survival curve for a the nivolumab treatment arm, and b the investigator’s choice treatment arm. REL relapse, TOX toxicity, TWiST time without symptoms of disease progression or toxicity
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.